C3GN associated with deletion in CHFR1 and CHFR3 genes: a case report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20253194Keywords:
C3GN, aHUS, CHFR 3 gene, Dense deposit disease, MPGNAbstract
C3GN is a unique abnormality that commonly occurs due to an abnormal alternative path of the complement complex. This is distinguished by precipitation of mainly the C3 factor of complement along with minimal deposit of immunoglobulin in the mesangial, subepithelial, and subendothelial areas of glomeruli. It is seen that most of the mutations that are pathogenic happen in C3, complement factor B (CFB), complement factor H (CFH), complement factor I, along with CFHR5. Some other associations are also found that could lead to this disorder, such as autoantibodies against C3 nephrotic factor, C5 nephritic factor, anti-CFB autoantibodies, along with anti-CHF antibodies. Atypical HUS occurs due to abnormality in different components of the alternate pathway, such as complement factor F, and autoantibodies against anti-CFH caused by CFHR 1 and 3 deletions. Here we narrate a rare occurrence of C3GN related to mutation in CFHR1 and 3 in a young female and her mother who presented to us for renal transplant as prospective recipient with her mother as donor.
Metrics
References
Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Update on C3 glomerulopathy: a complement-mediated disease. Nephron. 2020;144(6):272-80. DOI: https://doi.org/10.1159/000507254
Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol. 2015;11(1):14-2. DOI: https://doi.org/10.1038/nrneph.2014.217
Ahmad SB, Bomback AS. C3 glomerulopathy: pathogenesis and treatment. Adv Chronic Kidney Dis 2020;27(2):104-10. DOI: https://doi.org/10.1053/j.ackd.2019.12.003
Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16(2):555-3. DOI: https://doi.org/10.1681/ASN.2004050380
Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, et al. Clinical features of anti-factor H autoantibody associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010;21(12):2180-7. DOI: https://doi.org/10.1681/ASN.2010030315
Riedl M, Thorner P, Licht C. C3 glomerulopathy. Pediatr Nephrol. 2017;32(1):43-57. DOI: https://doi.org/10.1007/s00467-015-3310-4
Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet. 2010;376(9743):794-801. DOI: https://doi.org/10.1016/S0140-6736(10)60670-8
Holmes LV, Strain L, Staniforth SJ, Moore I, Marchbank K, Kavanagh D, et al. Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32. PLoS One. 2013;8(4):e60352. DOI: https://doi.org/10.1371/journal.pone.0060352
Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-59. DOI: https://doi.org/10.2215/CJN.02210310
Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554-62. DOI: https://doi.org/10.2215/CJN.04760512
Downloads
Published
How to Cite
Issue
Section
